Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by inthnoon Jun 27, 2024 5:37pm
104 Views
Post# 36109787

RE:RE:RE:RE:RE:It Was Just A Typo

RE:RE:RE:RE:RE:It Was Just A Typo
My god some people are so full of themselves and now more predictions.
BTW the poa is a mistake and is not in need of a correction and the company considers the matter closed and is a non issue.
And why are some still believing that MC exercised 350k options when it does not show on sedi or any other docs or in the quartelry reports under their holdings.
Just can't admit their mistakes but like to tell everyone else that they are wrong.
Time to move on and do not think that panc has taken a back seat at all. Today's announcement is only the start of guidance as we do not know the number of patients or the use of biomarkers, the sites or who will even possibly partner.
Still thinking that the scaa trial is the quickest to approval and that Roche will be the one to step up with either a partner ship or BO. And as for timing , people have been predictiing a partnership or BO for a few years now so we can only hope that eventually it will happen.
So let's hope that they are negotiatiing in good faith and that they are in the blackout as indicated by the non declaration of the December 2023 options.
<< Previous
Bullboard Posts
Next >>